Moreover, a recent 18F-florzolotau PET study showed that patients with clinical diagnosis of FTD can be classified into putative neuropathology-based subgroups (3R-like, 4R-like, AD-like, and tau-negative) based on visual and quantitative PET assessments [7]. The gene discussed is MAPT; the disease is frontotemporal dementia.